Skip to Content
Merck
CN

A1774

Amikacin disulfate salt

potency: 674-786 μg per mg (as amikacin base)

Synonym(s):

(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide disulfate, Antibiotic BB-K8 sulfate

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H43N5O13 · 2H2SO4
CAS Number:
39831-55-5
Molecular Weight:
781.76
Beilstein:
6172633
EC Number:
254-648-6
MDL number:
MFCD00167475
UNSPSC Code:
51281632
PubChem Substance ID:
24890586
NACRES:
NA.85

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

synthetic

Quality Level

200

form

powder or crystals

potency

674-786 μg per mg (as amikacin base)

color

white to off-white

antibiotic activity spectrum

Gram-negative bacteria
mycobacteria

Mode of action

protein synthesis | interferes

storage temp.

2-8°C

SMILES string

OS(O)(=O)=O.OS(O)(=O)=O.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O

InChI

1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1

InChI key

FXKSEJFHKVNEFI-GCZBSULCSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Chemical structure: aminoglycoside

Application

Amikacin is an aminoglycoside antibiotic commonly used in the treatment of drug-resistant mycobacteria . It is used to study organism-directed delivery of antibiotics as well as drug resistance .

Biochem/physiol Actions

Amikacin prevents bacterial protein synthesis by binding to the 30S ribosome subunit and inducing mRNA misreading.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H317,H361fd

Hazard Classifications

Repr. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000509260
0000509260
0000426449
0000426449
0000424100

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A M Lovering et al.
The Journal of antimicrobial chemotherapy, 43(5), 719-721 (1999-06-26)
Antibiotic-free human serum was spiked with known concentrations of liposomal amikacin and assayed on the Abbott TDx System, using polarization fluoroimmuno assay (PFIA) kits from Abbott Laboratories, Oxis and Sigma. Although all three kits gave a linear response, the Abbott
Targeted Delivery of Amikacin into Granuloma.
Ana Montes-Worboys, et al.
American Journal of Respiratory Cell and Molecular Biology, 182, 1546-1553 (2010)
Dorota Wrześniok et al.
Toxicology in vitro : an international journal published in association with BIBRA, 27(3), 1102-1108 (2013-02-19)
Amikacin is principally used to treat infections caused by microorganisms resistant to other aminoglycosides. Ototoxicity is one of the side effects of amikacin, but the causative mechanism of damage to the ear has not been fully established. Thus, the aim
Anna Belcarz et al.
International journal of pharmaceutics, 454(1), 285-295 (2013-07-16)
Following the quest for new composite materials for bone tissue engineering, a novel elastic hydroxyapatite-glucan composite loaded with two aminoglycoside antibiotics was prepared. The porosity of the composite and the drug release profiles in closed-loop and semi-open systems were tested.
Kenneth S Chen et al.
Pediatric blood & cancer, 60(11), 1772-1777 (2013-06-22)
Children undergoing cancer therapy often receive aminoglycosides to treat febrile neutropenia or gram-negative infections. The magnitude of the risk of developing aminoglycoside-induced ototoxicity and the dose threshold at which that risk significantly increases are unknown. Eligible cancer patients received the
View All Related Papers

Related Content

Product Information Sheet - A1774

Product Information Sheet

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service